Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
The effective therapy for pulmonary arterial hypertension (PAH) with inadequate clinical response is scarce except for lung transplantation when prostacyclin infusion is ineffective. The purpose of this study is to investigate the efficacy and safety of selexipag in addition to the infusion of prost...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | Respiratory Medicine Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213007122000144 |
| _version_ | 1818338844086370304 |
|---|---|
| author | Mizuki Momoi Takahiro Hiraide Yoshiki Shinya Hiromi Momota Shogo Fukui Michiyuki Kawakami Keiichi Fukuda Masaharu Kataoka |
| author_facet | Mizuki Momoi Takahiro Hiraide Yoshiki Shinya Hiromi Momota Shogo Fukui Michiyuki Kawakami Keiichi Fukuda Masaharu Kataoka |
| author_sort | Mizuki Momoi |
| collection | DOAJ |
| description | The effective therapy for pulmonary arterial hypertension (PAH) with inadequate clinical response is scarce except for lung transplantation when prostacyclin infusion is ineffective. The purpose of this study is to investigate the efficacy and safety of selexipag in addition to the infusion of prostacyclin. Nine patients [median 38 (36–49) years of age; 78% female] with PAH whose clinical response was inadequate despite the use of prostacyclin infusion analogs, were evaluated. Addition of selexipag significantly improved hemodynamics and no serious adverse events were observed. Selexipag with prostacyclin infusion analogs can be an effective therapeutic strategy for the PAH patients with inadequate clinical response. |
| first_indexed | 2024-12-13T15:17:34Z |
| format | Article |
| id | doaj.art-6e5f35878ea64174bff1729930596f24 |
| institution | Directory Open Access Journal |
| issn | 2213-0071 |
| language | English |
| last_indexed | 2024-12-13T15:17:34Z |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Respiratory Medicine Case Reports |
| spelling | doaj.art-6e5f35878ea64174bff1729930596f242022-12-21T23:40:40ZengElsevierRespiratory Medicine Case Reports2213-00712022-01-0136101592Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertensionMizuki Momoi0Takahiro Hiraide1Yoshiki Shinya2Hiromi Momota3Shogo Fukui4Michiyuki Kawakami5Keiichi Fukuda6Masaharu Kataoka7Department of Cardiology, Keio University School of Medicine, Tokyo, JapanDepartment of Cardiology, Keio University School of Medicine, Tokyo, JapanDepartment of Cardiology, Keio University School of Medicine, Tokyo, JapanDepartment of Cardiology, Keio University School of Medicine, Tokyo, JapanDepartment of Rehabilitation, Keio University Hospital, Tokyo, JapanDepartment of Rehabilitation Medicine, Keio University School of Medicine, Tokyo, JapanDepartment of Cardiology, Keio University School of Medicine, Tokyo, JapanDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan; Second Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan; Corresponding author. Second Department of Internal Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-Ku, Kitakyushu, Fukuoka, 807-8555, Japan.The effective therapy for pulmonary arterial hypertension (PAH) with inadequate clinical response is scarce except for lung transplantation when prostacyclin infusion is ineffective. The purpose of this study is to investigate the efficacy and safety of selexipag in addition to the infusion of prostacyclin. Nine patients [median 38 (36–49) years of age; 78% female] with PAH whose clinical response was inadequate despite the use of prostacyclin infusion analogs, were evaluated. Addition of selexipag significantly improved hemodynamics and no serious adverse events were observed. Selexipag with prostacyclin infusion analogs can be an effective therapeutic strategy for the PAH patients with inadequate clinical response.http://www.sciencedirect.com/science/article/pii/S2213007122000144Drug combinationsSelexipagProstacyclin |
| spellingShingle | Mizuki Momoi Takahiro Hiraide Yoshiki Shinya Hiromi Momota Shogo Fukui Michiyuki Kawakami Keiichi Fukuda Masaharu Kataoka Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension Respiratory Medicine Case Reports Drug combinations Selexipag Prostacyclin |
| title | Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension |
| title_full | Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension |
| title_fullStr | Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension |
| title_full_unstemmed | Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension |
| title_short | Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension |
| title_sort | impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension |
| topic | Drug combinations Selexipag Prostacyclin |
| url | http://www.sciencedirect.com/science/article/pii/S2213007122000144 |
| work_keys_str_mv | AT mizukimomoi impactofadditionalselexipagonprostacyclininfusionanalogsinpatientswithpulmonaryarterialhypertension AT takahirohiraide impactofadditionalselexipagonprostacyclininfusionanalogsinpatientswithpulmonaryarterialhypertension AT yoshikishinya impactofadditionalselexipagonprostacyclininfusionanalogsinpatientswithpulmonaryarterialhypertension AT hiromimomota impactofadditionalselexipagonprostacyclininfusionanalogsinpatientswithpulmonaryarterialhypertension AT shogofukui impactofadditionalselexipagonprostacyclininfusionanalogsinpatientswithpulmonaryarterialhypertension AT michiyukikawakami impactofadditionalselexipagonprostacyclininfusionanalogsinpatientswithpulmonaryarterialhypertension AT keiichifukuda impactofadditionalselexipagonprostacyclininfusionanalogsinpatientswithpulmonaryarterialhypertension AT masaharukataoka impactofadditionalselexipagonprostacyclininfusionanalogsinpatientswithpulmonaryarterialhypertension |